Blueprint Medicines Corporation (BPMC)
Jul 18, 2025 - BPMC was delisted (reason: acquired by SNY)
129.46
0.00 (0.00%)
Inactive · Last trade price on Jul 17, 2025
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Blueprint Medicines stock had an average target of 128.87, with a low estimate of 105 and a high estimate of 138.
Price Target: $128.87 (-0.46%)
Analyst Consensus: Buy
* Price targets were last updated on Jun 17, 2025.
Analyst Ratings
The average analyst rating for Blueprint Medicines stock from 18 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 6 | 6 | 4 | 4 |
| Buy | 7 | 8 | 8 | 8 | 2 | 1 |
| Hold | 5 | 6 | 6 | 6 | 14 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 19 | 22 | 21 | 21 | 20 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $143 → $129 | Buy → Hold | Downgrades | $143 → $129 | -0.36% | Jun 17, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $102 → $129 | Hold | Maintains | $102 → $129 | -0.36% | Jun 5, 2025 |
| UBS | UBS | Hold Maintains $88 → $129 | Hold | Maintains | $88 → $129 | -0.36% | Jun 5, 2025 |
| Citigroup | Citigroup | Strong Sell → Hold Upgrades $83 → $129 | Strong Sell → Hold | Upgrades | $83 → $129 | -0.36% | Jun 4, 2025 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 3, 2025 |
Financial Forecast
Revenue This Year
735.04M
from 508.82M
Increased by 44.46%
Revenue Next Year
975.99M
from 735.04M
Increased by 32.78%
EPS This Year
-0.91
from -1.07
EPS Next Year
0.99
from -0.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 811.7M | 1.1B | |||
| Avg | 735.0M | 976.0M | |||
| Low | 692.4M | 841.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.5% | 45.0% | |||
| Avg | 44.5% | 32.8% | |||
| Low | 36.1% | 14.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.24 | 3.22 | |||
| Avg | -0.91 | 0.99 | |||
| Low | -2.05 | -1.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.